1,4-二噁烷,2-溴- | 179690-41-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 中文名称: 1,4-二噁烷,2-溴-
• 英文名称: 2-Bromo-1,4-dioxane
• CAS: 179690-41-6
• 化学式: C₄H₇BrO₂
• 分子量: 167.0
• InChiKey: OTVGARFFAAFRAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4-乙酰基苯基)乙酸甲酯 、 1,4-二噁烷,2-溴- 生成 p-Methoxycarbonylmethylphenylacetyl bromide
  参考文献：
  名称：

  Piperazine derivatives, medicaments comprising these compounds, their

  摘要：

  本发明涉及一般式为##STR1##的哌嗪衍生物，其中R.sub.a，Y.sub.1至Y.sub.3和E在此定义，其互变异构体、立体异构体，包括其混合物和盐，特别是与无机或有机酸或碱的生理耐受盐。这些化合物具有有价值的药理学特性，如抑制聚集活性。本发明还涉及包含这些化合物的药物以及制备这些化合物的过程。

  公开号：

  US05922717A1

文献信息

• Piperazine derivatives, pharmaceutical compositions containing these
  申请人：Karl Thomae, GmbH

  公开号：US05700801A1

  公开（公告）日：1997-12-23

  Piperazine derivatives useful in the treatment or prevention of inflammation, bone degradation, thrombosis and tumor metastasis. Exemplary species are: (a) \x9b4-trans-\x9b3-\x9b4-(4-Pyridyl)-piperazin-1-yl!propionyl!amino!-cyclohexanecarb oxylic acid, (b) 3-\x9b4-trans-\x9b4-(4-Pyridyl)-piperazin-1-yl!carbonylamino!-cyclohexylpropioni c acid, (c) 3-\x9b4-trans-\x9b4-(4-Pyridyl)-piperazin-1-yl!malonylamino!cyclohexylcarboxylic acid, (d) Methyl \x9b4-trans-\x9b3-\x9b4-(4-pyridyl)-piperazin-1-yl!-propionyl!-amino!cyclohexane carboxylate, (e) Methyl 3-\x9b4-trans-\x9b4-(4-pyridyl)-piperazin-1-yl!-carbonylamino!cyclohexyl propionate, (f) Methyl \x9b4-trans-\x9b4-(4-pyridyl)-piperazin-1-yl!-malonylamino!-cyclohexyl carboxylate, (g) Cyclohexyl \x9b4-trans-\x9b\x9b4-(4-pyridyl)-piperazin-1-yl!-acetyl!-amino!-cyclohexane carboxylate, and (h) Isobutyl \x9b4-trans-\x9b\x9b4-(4-pyridyl)-piperazin-1-yl!-acetyl!-amino!-cyclohexane carboxylate.

  哌嗪衍生物可用于治疗或预防炎症、骨质破坏、血栓形成和肿瘤转移。其中一些种类包括：(a) \x9b4-顺- \x9b3-\x9b4-(4-吡啶基)-哌嗪-1-基!丙酰基!氨基!-环己烷羧酸，(b) 3-\x9b4-顺- \x9b4-(4-吡啶基)-哌嗪-1-基!羰基氨基!-环己基丙酸，(c) 3-\x9b4-顺- \x9b4-(4-吡啶基)-哌嗪-1-基!马来酰氨基!环己基羧酸，(d) 甲基 \x9b4-顺- \x9b3-\x9b4-(4-吡啶基)-哌嗪-1-基!-丙酰基!-氨基!环己烷羧酸甲酯，(e) 甲基 3-\x9b4-顺- \x9b4-(4-吡啶基)-哌嗪-1-基!-羰基氨基!环己基丙酸甲酯，(f) 甲基 \x9b4-顺- \x9b4-(4-吡啶基)-哌嗪-1-基!-马来酰氨基!-环己基羧酸甲酯，(g) 环己基 \x9b4-顺-\x9b\x9b4-(4-吡啶基)-哌嗪-1-基!-乙酰基!-氨基!环己烷羧酸酯，以及(h) 异丁基\x9b4-顺-\x9b\x9b4-(4-吡啶基)-哌嗪-1-基!-乙酰基!-氨基!环己烷羧酸酯。
• Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
  申请人：Wong C.W. Norman

  公开号：US20060205767A1

  公开（公告）日：2006-09-14

  The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.

  本公开提供了非自然产生的多酚化合物，其可上调载脂蛋白A-I（ApoA-I）的表达。所公开的组合物和方法可用于治疗和预防心血管疾病及相关疾病状态，包括胆固醇或脂质相关障碍，例如动脉粥样硬化等。
• FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
  申请人：Wong Norman C.W.

  公开号：US20090259048A1

  公开（公告）日：2009-10-15

  The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.

  本公开提供了一些非自然生成的多酚化合物，它们可以上调载脂蛋白A-I（ApoA-I）的表达。所公开的组合物和方法可用于治疗和预防心血管疾病及相关疾病状态，包括胆固醇或脂质相关的疾病，如动脉粥样硬化等。
• Piperazine derivatives, medicaments comprising these compounds, their
  申请人：Dr. Karl Thomae GmbH

  公开号：US05922717A1

  公开（公告）日：1999-07-13

  The present invention relates to piperazine derivatives of the general formula ##STR1## in which R.sub.a, Y.sub.1 to Y.sub.3 and E are defined herein, tautomers thereof, stereoisomers thereof, including their mixtures, and salts thereof, and in particular physiologically tolerated salts thereof with inorganic or organic acids or bases. These compounds have valuable pharmacological properties, such as aggregation-inhibiting activity. This invention also relates to medicaments comprising these compounds and to processes for the preparation of these compounds.

  本发明涉及一般式为##STR1##的哌嗪衍生物，其中R.sub.a，Y.sub.1至Y.sub.3和E在此定义，其互变异构体、立体异构体，包括其混合物和盐，特别是与无机或有机酸或碱的生理耐受盐。这些化合物具有有价值的药理学特性，如抑制聚集活性。本发明还涉及包含这些化合物的药物以及制备这些化合物的过程。